• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Tandem reports positive research for its artificial pancreas tech

April 17, 2023 By Chris Newmarker

Tandem Diabetes Care t:slim 2 Control-IQ artificial pancreas
The artificial pancreas using Tandem Diabetes Care and Dexcom technology. [Image from Tandem Diabetes Care]
Tandem Diabetes Care (Nasdaq:TNDM) today announced a positive meta-analysis of three randomized controlled trials of its Control-IQ advanced hybrid closed-loop technology.

The research found immediate and sustained improvements for a diverse range of subjects using Control-IQ technology, according to the research published in the journal Diabetes Technology & Therapeutics. There was an average increase in time in range of 2.8 hours and a reduction in hemoglobin A1c compared to control groups in people ages 2 to 72 years old.

“Control-IQ technology delivered the most robust improvements in those entering the study with the highest hemoglobin A1c and lowest time in range,” Dr. Roy W. Beck, executive director of the Jaeb Center for Health Research (Tampa, Florida), said in a news release. “The high number of automatic boluses given by the system in this group likely reflect previously missed meal boluses or lack of manual correction boluses when on conventional therapy and demonstrates the substantial impact Control-IQ technology’s auto-bolusing feature can have for people struggling on a standard pump or multiple daily injections.”

Boris Kovatchev, director of the Center for Diabetes Technology at the University of Virginia, noted that the study found Control-IQ benefits regardless of age, ethnicity, education, or previous pump experience. “It is clear from these results, which are consistent with real-life data from thousands of current Control-IQ technology users, that this technology should be considered as an option for anyone living with type 1 diabetes.”

Dr. Jordan Pinsker, VP and medical director at Tandem Diabetes Care, said the three randomized, controlled trials have provided Control-IQ with the most robust data set supporting its benefits compared to any other automated insulin delivery system that is presently out there.

Tandem’s Control-IQ technology automatically observes and manages blood glucose levels. This artificial pancreas employs an insulin pump that uses sophisticated algorithms based on glucose monitoring data from the Dexcom G6 CGM, adjusting insulin dosage as required. The FDA has cleared Control-IQ for use in individuals aged 6 and older with type 1 diabetes.

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured Tagged With: artificial pancreas, Dexcom, Tandem Diabetes Care

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

About Chris Newmarker

Chris Newmarker is the executive editor of WTWH Media life science's news websites and publications including MassDevice, Medical Design & Outsourcing and more. A professional journalist of 18 years, he is a veteran of UBM (now Informa) and The Associated Press whose career has taken him from Ohio to Virginia, New Jersey and, most recently, Minnesota. He’s covered a wide variety of subjects, but his focus over the past decade has been business and technology. He holds bachelor’s degrees in journalism and political science from Ohio State University. Connect with him on LinkedIn or email at cnewmarker@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS